Torigen Pharmaceuticals Inc.
Provides veterinary cancer care solutions for companion animals
Torigen Pharmaceuticals, Inc. is focused on providing veterinary cancer solutions for companion animals. Their product, VetiVax(TM) is a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight cancer. When combined with an innovative bulking agent, MIMTM (Matrix Immune Modulator) an overall reduction in tumor size and inhibition of metastasis have been noted. Torigen’s treatment can work for multiple tumor indications treating over 2,000,000 companion animals diagnosed with cancer each year. After completing an initial Phase I safety trial, VetiVax(TM) has been proven safe and veterinarians believe that this product could truly disrupt the market while helping animals with cancer.
Ashley Kalinauskas, CEO